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Abstract
Pediatric chronic kidney disease (CKD) is characterized by many co-morbidities, including impaired growth and development, CKD-mineral and bone disorder, anemia, dysregulated iron metabolism, and cardiovascular disease. In pediatric
CKD cohorts, higher circulating concentrations of fibroblast growth factor 23 (FGF23) are associated with some of these
adverse clinical outcomes, including CKD progression and left ventricular hypertrophy. It is hypothesized that lowering
FGF23 levels will reduce the risk of these events and improve clinical outcomes. Reducing FGF23 levels in CKD may be
accomplished by targeting two key stimuli of FGF23 production—dietary phosphate absorption and iron deficiency. Ferric
citrate is approved for use as an enteral phosphate binder and iron replacement product in adults with CKD. Clinical trials in
adult CKD cohorts have also demonstrated that ferric citrate decreases circulating FGF23 concentrations. This review outlines the possible deleterious effects of excess FGF23 in CKD, summarizes data from the adult CKD clinical trials of ferric
citrate, and presents the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) study, a randomized, placebocontrolled trial to evaluate the effects of ferric citrate on FGF23 in pediatric patients with CKD stages 3–4 (ClinicalTrials.
gov Identifier NCT04741646).
Keywords Pediatrics · Chronic kidney disease · Ferric citrate · Fibroblast growth factor 23

Introduction
Childhood and adolescence are crucial times for healthy
growth and development. Children with chronic kidney
disease (CKD) suffer from suboptimal growth, impaired
neurocognitive development, and multisystemic organ dysfunction, which manifests as multiple CKD-associated comorbidities, including CKD-mineral bone disorder (CKDMBD) [1, 2], dysregulated iron metabolism [3, 4], anemia
[3], and cardiovascular disease [5]. The adverse effects of
these CKD-associated co-morbidities can have long-lasting
consequences that persist into adulthood, contributing to a
* Isidro B. Salusky
isalusky@mednet.ucla.edu
Extended author information available on the last page of the article

markedly reduced life expectancy for children with CKD
[6]. Amelioration of these conditions may improve clinical
outcomes for pediatric patients with CKD.
Contributing to these interrelated CKD co-morbidities is
fibroblast growth factor 23 (FGF23), a predominantly bonederived phosphaturic hormone. Circulating concentrations
of FGF23 increase early in the course of adult [7] and pediatric [8] CKD—before other traditional markers of CKDMBD such as serum phosphate and parathyroid hormone—
and continue to increase as kidney function declines. In both
adult and pediatric CKD cohorts, higher FGF23 concentrations are independently associated with adverse clinical
outcomes, including left ventricular hypertrophy [9, 10] and
CKD progression [11–13]. Multiple factors stimulate FGF23
production, including dietary phosphate absorption [14, 15]
and iron deficiency [16]. Targeting the stimuli of FGF23
production may lower circulating FGF23 concentrations and
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may reduce the development of FGF23-associated adverse
clinical outcomes.
Recently, ferric citrate (Auryxia, Akebia Therapeutics,
Inc., Cambridge, MA) was approved for clinical use as an
enteral phosphate binder in adult patients with CKD on dialysis, and as an iron replacement product in adult patients
with non-dialysis-dependent CKD and iron deficiency anemia [17]. By decreasing dietary phosphate absorption and
improving iron status, ferric citrate may mitigate two stimuli
for excess FGF23 production in CKD, leading to decreased
circulating FGF23 concentrations (Fig. 1). In this review,
we will describe the potentially deleterious effects of FGF23
in CKD; summarize the published data from clinical trials in adults evaluating ferric citrate in CKD; and present
the background, hypotheses, and design features of the
NIDDK-funded Ferric Citrate and Chronic Kidney Disease
in Children (FIT4KiD) study, a 12-month, double-blind, randomized, placebo-controlled trial to evaluate the effects of
ferric citrate on changes in FGF23 levels in pediatric patients
with CKD stages 3–4.

Fibroblast growth factor 23
FGF23 is an essential hormone secreted mainly by osteocytes that physiologically regulates phosphate and 1,25-dihydroxyvitamin D (1,25(OH)2D). FGF23 decreases expression
of the type II sodium-phosphate cotransporters (NaPi-2a and
NaPi-2c) in renal proximal tubules, reducing renal phosphate reabsorption [18, 19]. FGF23 also decreases expression of renal 1α-hydroxylase, the enzyme that converts
25(OH)D to active 1,25(OH)2D, and increases expression
of renal 24-hydroxylase, the enzyme that converts 25(OH)
Fig. 1  Ferric citrate inhibits two
stimuli of FGF23 production,
dietary phosphate absorption
and iron deficiency. Lowering
circulating FGF23 concentrations may prevent the development of various FGF23-associated, off-target, adverse effects
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D and 1,25(OH)2D to inactive metabolites, thus decreasing
overall renal 1,25(OH)2D production [20–22]. Decreased
renal phosphate reabsorption and decreased 1,25(OH)2Dmediated enteral phosphate absorption results in decreased
serum phosphate concentrations. Therefore, in the setting of
phosphate loading or hyperphosphatemia, an increase in circulating FGF23 levels directly induces phosphate excretion
and indirectly reduces dietary phosphate absorption, thus
maintaining normal circulating phosphate concentrations. In
the setting of CKD, bone [23] and circulating [7, 8, 24, 25]
levels of FGF23 increase early and continue to increase as
kidney function declines [7, 8, 24–26], helping to maintain
normophosphatemia until late-stage CKD [7, 8].

Adverse effects of increased FGF23 concentrations
in CKD
Although progressively increasing FGF23 concentrations in
CKD help to prevent or mitigate hyperphosphatemia, elevated FGF23 levels have also been independently associated
with a multitude of adverse “off-target” effects. Most notably, FGF23 has emerged as a potential mediator of cardiac
hypertrophy, independent of hypertension and vascular calcification [27]. Studies conducted in vitro and in mice have
demonstrated that FGF23 directly induces cardiac myocyte
hypertrophy [9] by binding to cardiomyocyte FGF receptor
4 (FGFR4), inducing the downstream phosphorylation of
phospholipase Cγ (PLCγ) and the activation of calcineurinnuclear factor of activated T-cells (NFAT) signaling pathways that affect genes regulating cardiac remodeling [28,
29]. Consistent with these pre-clinical observations, in both
the adult Chronic Renal Insufficiency Cohort (CRIC) study
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[9] and the pediatric Chronic Kidney Disease in Children
(CKiD) study [10], higher circulating FGF23 concentrations
were independently associated with left ventricular hypertrophy. Furthermore, FGF23 may have additional adverse
cardiac effects. Pre-clinical studies demonstrate that FGF23
alters cardiomyocyte intracellular calcium concentrations
[30, 31] and induces pro-arrhythmogenic activity [31].
Potentially consistent with these observations, in the CRIC
study, higher FGF23 levels were independently associated
with prevalent and incident atrial fibrillation [32].
Increased circulating FGF23 concentrations in CKD
may also have extra-cardiac adverse effects. In multiple
adult (CRIC [12] and the Mild to Moderate Kidney Disease
(MMKD) study [11]) and pediatric (CKiD [13]) cohorts,
higher FGF23 levels were independently associated with a
more rapid rate of CKD progression, even after adjustment
for traditional CKD progression risk factors. Regarding
CKD-MBD, FGF23-mediated suppression of 1,25(OH)2D
production promotes secondary hyperparathyroidism [33].
Regarding CKD-associated anemia, murine in vivo studies
suggest that FGF23 may have inhibitory effects on erythropoiesis [34, 35] and, in the CRIC study, higher FGF23 levels
were independently associated with prevalent and incident
anemia [36]. FGF23 may also impact the immune system,
as pre-clinical studies demonstrate that in CKD, increased
FGF23 levels are associated with impaired neutrophil activation [37]. In the Hemodialysis (HEMO) study cohort, higher
FGF23 levels were independently associated with infectionrelated hospitalization or death [38]. Possibly due to these
cardiac and extra-cardiac adverse effects, higher circulating
concentrations of FGF23 in CKD are independently associated with increased overall mortality rates [12, 39, 40].

FGF23 production
Given the possible multisystemic adverse effects of increased
FGF23 concentrations in CKD, it can be hypothesized that
lowering FGF23 levels in patients with CKD may improve
clinical outcomes. One potential mechanism to lower FGF23
levels is to target the stimuli that increase FGF23 production.
Multiple factors stimulate FGF23 production, central among
which is dietary phosphate absorption [14, 15]. In studies
of healthy volunteers, a phosphate-depleted diet decreased
circulating FGF23 concentrations [14, 15], and a phosphateloaded diet increased circulating FGF23 concentrations [15].
Recently, iron deficiency has been identified as a novel
stimulus of FGF23 production. Several murine studies demonstrate that iron deficiency potently induces Fgf23 mRNA
expression [41–44]. Iron deficiency also concurrently
increases intracellular FGF23 post-translational proteolytic
cleavage, resulting in secretion of FGF23 protein fragments from the cell [41–44]. However, in CKD, FGF23 proteolytic cleavage may be impaired [45–47], thus uncoupling
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iron deficiency-induced increased FGF23 transcription from
its post-translational cleavage. Therefore, in the absence of
CKD, iron deficiency results in increased circulating concentrations of FGF23 fragments; however, in the presence
of CKD, iron deficiency may increase concentrations of fulllength FGF23. Indeed, in a pre-clinical study of mice with
and without experimental CKD fed an iron-deficient diet,
whole bone Fgf23 mRNA expression and plasma concentrations of total (intact + fragmented) FGF23 increased to a
similar degree in both the non-CKD and CKD groups, but
the increase in plasma concentrations of full-length, intact
FGF23 was much greater in the mice with CKD [44]. The
median percentage of circulating FGF23 that was intact was
only 12% in the non-CKD iron-deficient mice, but was 72%
in the CKD iron-deficient group [44]. Therefore, iron deficiency, which is common in pediatric patients with CKD
[48, 49], may represent a novel factor contributing to elevated intact FGF23 levels in CKD.
For human samples, there are commercial assays to measure both C-terminal FGF23 and intact FGF23 [50]. The
C-terminal assay captures both intact FGF23 and C-terminal
FGF23 fragments, thus measuring total (intact + fragmented)
FGF23 concentrations. Conversely, the intact assay captures
only intact FGF23 (iFGF23). In human CKD cohorts, iron
deficiency is associated with increased concentrations of
circulating total FGF23, as measured by the C-terminal
FGF23 assay [51, 52]. Associations between iron status and
intact FGF23 levels have not been specifically evaluated in
large CKD cohorts; however, given that FGF23 cleavage
is impaired in CKD [45–47], it is hypothesized that iron
deficiency in CKD would increase intact FGF23 to a greater
degree than iron deficiency in the absence of CKD would.
In the FIT4KiD trial, the primary outcome is changes in
iFGF23, as this is considered to be the biologically active
FGF23 moiety, but total FGF23 concentrations will also be
measured as an exploratory analysis.

Randomized controlled trials of ferric citrate
in adult patients with non‑dialysis‑dependent CKD
As ferric citrate can function as both a phosphate binder
and a source of iron, it can both decrease enteral phosphate
absorption and improve iron status in CKD, thus targeting
two of the mechanisms that increase FGF23 levels. Multiple randomized, placebo-controlled trials have evaluated
the effects of ferric citrate on serum phosphate, iron status, and FGF23 levels in adult patients with non-dialysisdependent CKD. In a study published in 2014, Yokoyama
et al. conducted a 12-week, randomized trial of ferric citrate
vs. placebo in 86 Japanese patients with CKD stages 3–5
[53]. Compared to placebo, ferric citrate decreased serum
phosphate concentrations, increased transferrin saturation
and ferritin, and decreased circulating iFGF23 levels. In a
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similar study published in 2015, Block et al. conducted a
12-week, randomized trial of ferric citrate vs. placebo in
141 American patients with CKD stages 3–5 [54]. Compared to placebo, ferric citrate decreased serum phosphate
concentrations; increased transferrin saturation, ferritin,
and hemoglobin; and decreased circulating iFGF23 levels.
Lastly, in a study published in 2017, Fishbane et al. conducted a 16-week, randomized trial of ferric citrate vs. placebo in 233 American patients with CKD stages 3–5 [55].
Compared to placebo, ferric citrate decreased serum phosphate concentrations; increased transferrin saturation, ferritin, and hemoglobin; and decreased circulating iFGF23
levels. More recently, in a study published in 2019, Block
et al. conducted a 36-week randomized trial of ferric citrate
vs. standard of care in 199 patients with advanced CKD
(eGFR < 20 ml/min/1.73 m2) [56]. Compared to standard
of care, ferric citrate decreased serum phosphate concentrations; increased transferrin saturation, ferritin, and hemoglobin; and decreased circulating iFGF23 levels. Details of

these randomized trials are presented in Table 1, demonstrating the beneficial effects of ferric citrate on phosphate, iron,
and FGF23 in the setting of CKD. The primary objective of
the FIT4KiD trial, described below, is to evaluate the effects
of ferric citrate on changes in circulating iFGF23 concentrations in a cohort of pediatric patients with CKD.
Additionally, the 2019 trial conducted by Block et al.
evaluated the effects of ferric citrate on a composite clinical endpoint that included death, provision of dialysis,
or transplantation. Compared to patients randomized to
standard of care, patients randomized to treatment with
ferric citrate had a lower incidence of the composite endpoint [56], suggesting possible direct or indirect benefits
of ferric citrate on clinical outcomes. However, in this
trial, there was some imbalance in the baseline characteristics of the ferric citrate and standard of care groups, with
significantly more diabetics randomized to the standard
of care group. Also, this pilot study included a standard
of care control, was open-label, and was conducted at a

Table 1  Randomized controlled trials of ferric citrate in adult patients with non-dialysis-dependent CKD. FC, ferric citrate; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; TSAT, transferrin saturation; FGF23, fibroblast growth factor 23; LS, least squares
Study

Study details

Study parameters

Effects of ferric citrate

Yokoyama et al. [53]

FC (n = 57) vs. placebo (n = 29)
12-week duration
Inclusive of CKD stages 3–5 (mean
eGFR 9 ml/min/1.73 m2)
Mean age 65 years

Phosphate
TSAT
Ferritin
Hemoglobin
FGF23

Block et al. [54]

FC (n = 72) vs. placebo (n = 69)
12-week duration
Inclusive of CKD stages 3–5 (mean
eGFR 24 ml/min/1.73 m2)
Mean age 65 years

Phosphate
TSAT
Ferritin
Hemoglobin
FGF23

Fishbane et al. [55]

FC (n = 117) vs. placebo (n = 116)
16-week duration
Inclusive of CKD stages 3–5 (mean
eGFR 29 ml/min/1.73 m2)
Mean age 65 years

Phosphate
TSAT
Ferritin
Hemoglobin
FGF23

Block et al. [56]

FC (n = 133) vs. usual care (n = 66)
36-week duration
Inclusive of eGFR < 20 ml/min/1.73 m
 2
2
(mean eGFR 14 ml/min/1.73 m )
Mean age 62 years

Phosphate
TSAT
Ferritin
Hemoglobin
FGF23

< 0.001
Decreased from mean 5.7 to 4.4 mg/dl
< 0.001
Increased from mean 27 to 44%
< 0.001
Increased from mean 69 to 204 ng/ml
0.23
Increased from mean 10.3 to 10.7 g/dl
< 0.001
Decreased from median 453 to 209 pg/
ml
< 0.001
Decreased from mean 4.5 to 3.9 mg/dl
< 0.001
Increased from mean 22 to 32%
< 0.001
Increased from mean 116 to 189 ng/ml
< 0.001
Increased from mean 10.5 to 11.0 g/dl
Decreased from median 159 to 105 pg/ 0.02
ml
0.02
Mean relative change vs. placebo
< 0.001
of − 0.2 mg/dl
< 0.001
Mean relative change vs. placebo
< 0.001
of + 18%
< 0.001
Mean relative change vs. placebo
of + 170 ng/ml
Mean relative change vs. placebo
of + 0.8 g/dl
Decreased from median 134 to 105 pg/
ml
< 0.001
Lower LS mean vs. usual care (4.2 vs.
< 0.001
4.6 mg/dl)
< 0.001
Increased with FC, unchanged with
< 0.001
usual care
< 0.001
Increased with FC, unchanged with
usual care
Increased with FC, decreased with usual
care
Unchanged with FC, increased with
usual care
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single center. Nevertheless, the encouraging results from
this pilot study informed the design of a larger (1,000
patients), multicenter, randomized, double-blind, placebocontrolled trial evaluating the effects of ferric citrate on
hard clinical endpoints (death, dialysis initiation, transplantation, hospitalization) in patients with advanced
CKD (eGFR < 20 ml/min/1.73 m2) — the FRONTIER trial
(Block et al. Abstract PO2381, ASN Kidney Week 2021).

Ferric citrate use in pediatric patients with CKD
No randomized controlled trials of ferric citrate have been
conducted in pediatric patients with CKD. However, one
center published their real-world experience with the off-label
use of ferric citrate in a small cohort of pediatric patients with
kidney failure on dialysis [57]. That retrospective analysis
included 11 patients on dialysis, most of whom were adolescents (median age at ferric citrate initiation 13 years, range
4 to 17 years). Ferric citrate was either added to patients’
phosphate binder regimens or patients were switched from
their current phosphate binders to ferric citrate. The median
duration of treatment with ferric citrate was 214 days (range
39 to 654 days). The authors compared time-averaged values for serum phosphate and iron-related parameters before
and after starting ferric citrate therapy. Administration of ferric citrate decreased serum phosphate concentrations from
a median (interquartile range) of 6.5 (5.5, 7.0) to 5.2 mg/dl
(5.1, 6.3) (p = 0.014), and decreased age-adjusted phosphate
standard deviation scores from 2.3 (1.5, 3.6) to 0.9 (0.0, 2.4)
(p = 0.019). Ferric citrate therapy also increased transferrin
saturation from 26 (17, 34) to 34% (28, 46) (p = 0.049), and
increased serum ferritin from 107 (86, 675) to 230 ng/ml (113,
716) (p = 0.074). This retrospective study suggests that ferric citrate may be efficacious in pediatric patients with CKD,
warranting further investigation in prospective clinical trials.
Ferric citrate appears to have acceptable tolerability,
although close monitoring of iron parameters is warranted.
In the above study, the maximum time-averaged transferrin saturation and serum ferritin observed while on ferric
citrate was 55% and 1,162 ng/ml, respectively. In studies
of adult patients with CKD treated with ferric citrate [54,
55], the most common adverse effects were gastrointestinal
symptoms, including discolored feces, diarrhea, constipation, and nausea [58]. However, in these studies, only 5.3%
of study subjects randomized to ferric citrate discontinued
the study drug because of gastrointestinal adverse effects
[58]. Similarly, in the above pediatric retrospective study,
no patient developed gastrointestinal adverse effects severe
enough to require dose reduction or discontinuation of ferric
citrate. The FIT4KiD trial, described below, will assess the
safety and tolerability of ferric citrate in pediatric patients
with CKD.
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The FIT4KiD trial
The FIT4KiD study is a phase 2, randomized, double-blind,
placebo-controlled trial, designed to evaluate the effects of
ferric citrate on iFGF23 in children with CKD stages 3–4.
Depending on eGFR, the prevalence of elevated FGF23 concentrations (as measured by the total FGF23 assay) in children with CKD stages 3–4 is ~ 60–100% [8]. FIT4KiD was
approved and is funded by NIH/NIDDK through a cooperative
agreement (U01-DK122013) among 12 clinical sites (Table 2).
The study protocol was approved by a central Institutional
Review Board (Washington University in St. Louis, IRB
#202012083, approved 2/26/21) and by the Data and Safety
Monitoring Board appointed by NIDDK (approved on 6/2/20).
The primary study hypothesis of the FIT4KiD trial is that
compared to placebo, active treatment with ferric citrate will
lower serum iFGF23 concentrations, measured over time
(Table 3). To test this hypothesis, the FIT4KiD trial will
recruit 160 pediatric participants between the ages of 6 and
17 years with CKD stages 3–4 (Table 4). After providing
informed consent, study participants will be randomized
to treatment with a weight-based dose of ferric citrate or
treatment with placebo and will be followed for 12 months
(Fig. 2). Participants weighing less than 31 kg will receive
3 g/day of ferric citrate; participants weighing greater than
31 kg but less than 51 kg will receive 5 g/day of ferric citrate;
and participants weighing 51 kg or more will receive 6 g/day
of ferric citrate. The total daily dosage will be divided into
three doses to be taken with meals. Weight-based dosing was
chosen instead of age-based dosing given that children with
CKD are frequently small for age. Additionally, since dietary
phosphate intake correlates with dietary caloric intake, and
the latter correlates with body weight, weight-based dosing
will best approximate dietary phosphate intake.
Table 2  Ferric Citrate and Chronic Kidney Disease in Children
(FIT4KiD) participating sites
Mattel Children’s Hospital at the University of California, Los Angeles (Los Angeles, CA)
(Data Coordinating Center)
Arnold Palmer Hospital for Children (Orlando, FL)
Benioff Children’s Hospital at the University of California, San Francisco (San Francisco, CA)
British Columbia Children’s Hospital (Vancouver, BC, Canada)
Children’s Healthcare of Atlanta (Atlanta, GA)
Children’s Hospital at Montefiore (Bronx, NY)
Children’s Hospital of Philadelphia (Philadelphia, PA)
Children’s Medical Center (Dallas, TX)
Children’s Mercy Kansas City (Kansas City, MO)
Cincinnati Children’s Hospital (Cincinnati, OH)
St. Christopher’s Hospital for Children (Philadelphia, PA)
Texas Children’s Hospital (Houston, TX)
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hypotheses. FC, ferric citrate;
FGF23, fibroblast growth factor
23
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Primary endpoint
Compared to placebo, from baseline, active treatment with FC will lower serum intact FGF23 concentrations
Safety and tolerability endpoint
Compared to placebo, active treatment with FC will be safe and tolerable
Secondary endpoints
Compared to placebo, from baseline, active therapy with FC will be associated with:
-Increased hemoglobin
-Increased serum transferrin saturation
-Increased serum ferritin
-Increased serum 1,25-dihydroxyvitamin D
-Decreased serum parathyroid hormone
Exploratory endpoints
Compared to placebo, from baseline, active therapy with FC will be associated with:
-Smaller decrease in estimated glomerular filtration rate
-Decreased bone FGF23
-Increased osteoid thickness
-Decreased biomarkers of bone turnover
-Decreased phosphaturia
-Increased serum calcium
-Increased serum klotho
-Decreased serum C-terminal (total) FGF23

Table 4  Participant inclusion and exclusion criteria
Inclusion criteria
Ages 6 to 17 years (inclusive)
Estimated glomerular filtration rate of 15–59 ml/min/1.73 m2 by the updated CKiD formula [60]
Serum phosphate within age-appropriate normal ranges
Serum ferritin < 500 ng/ml and transferrin saturation < 50%
For those patients treated with nutritional vitamin D, calcitriol, iron, and/or erythropoiesis-stimulating agents, doses must be stable for at least
2 weeks prior to screening
Able to swallow tablets
Able to eat at least two meals a day
In the opinion of the investigator, willing and able to follow the study treatment regimen and comply with the site investigator’s recommendations
Exclusion criteria
Current treatment with phosphate binders
History of allergic reactions, defined as rashes or hives, to ferric citrate or iron preparations
Current intestinal malabsorption, documented in the medical record
Anticipated initiation of dialysis or kidney transplantation within 6 months
Current or planned future systemic immunosuppressive therapy
Prior solid organ transplantation
Receipt of bone marrow transplant within 2 years of screening
Current pregnancy, current lactation, or female subjects who have reached puberty, unless using highly effective contraception
Patients participating in other interventional study (observational study participation is permitted)
Poor adherence to medical treatments in the opinion of the investigator

The primary analyses for this trial will evaluate changes
from baseline in iFGF23 concentrations over 12 months
between the treatment arm and the placebo arm. The analysis will use a linear mixed-effects model, with random
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participant effects accounting for repeated measurements, and
random site effects accounting for clustering of participants
into study sites. The model will include terms for treatment,
time, treatment by time interaction (primary term for the
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Fig. 2  The Ferric Citrate and Chronic Kidney Disease in Children
(FIT4KiD) trial schema. The FIT4KiD study is a randomized, double-blind, placebo-controlled, 12-month trial of 160 pediatric patients
with CKD stages 3–4. It will test the hypothesis that, compared to

placebo, ferric citrate will safely lower intact FGF23 levels. The study
design includes a screening visit, baseline assessments, and postrandomization scheduled follow-up. Further details are provided in
Table S1

inference in this study), baseline iFGF23, and stratification
factors (study site, CKD stage, and urine protein/creatinine
ratio) as covariates. Time will be modeled as two periods,
months 1–3 and months 6–12, with the primary test based on
the difference between treatment arms during the second time
period [54]. A single interim analysis will be performed at
50% completion of 3 months of treatment or the first quarter
of year 3 of the trial. The O’Brien/Fleming rules for interim
analysis were used, assigning an alpha of 0.0054 to the midpoint analysis, and 0.0492 to the final analysis [59].
To evaluate the power of the trial, we carried out a simulation study using the analysis approach described above.
Simulated data sets were created assuming that the mean
level of natural log-transformed iFGF23 is the same at baseline in both arms, changes linearly during the first 3 months,
is stable from 3 to 12 months in the treatment arm, and
remains constant over time in the placebo group, as previously reported [54]. We utilized data from the CKiD cohort
to estimate the design parameters (baseline mean, between
sites and within and between subjects standard deviations)
for the simulation. The simulation also assumed that 20%
of participants would be lost to follow-up by month 12. The
results of our simulation study showed that a sample size of
160 participants provides 80% power to detect a treatment
difference of 26% between treatment vs. placebo.
Given that ferric citrate has been associated with
improved hemoglobin concentrations [54–56], reductions in
serum parathyroid hormone [53], and improved kidney outcomes [56], secondary objectives of this study include determining the effects of ferric citrate on anemia, indices of bone
and mineral metabolism, and kidney function (Table 3).
Serum creatinine will be measured over time, and GFR will
be estimated using the updated CKiD formula [60].
We will also evaluate the safety and tolerability of ferric citrate, detailed in Table S1, including surveillance for

gastrointestinal intolerance, iron overload, and hypophosphatemia. As described in Table S1 and Figures S1–S10,
should gastrointestinal adverse effects, elevated transferrin
saturation or ferritin, and/or hypophosphatemia occur, then
study drug dosage will be adjusted. Regarding the possibility
of citrate-induced enhanced intestinal aluminum absorption
[61], in adult CKD studies, ferric citrate treatment was not
associated with increased serum aluminum concentrations
[17]. Nevertheless, as stated in the study protocol, administration of aluminum-containing compounds should be
avoided in study participants.
Additionally, 24 UCLA participants will undergo iliac
crest bone biopsy to determine the effect of ferric citrate
therapy on the bone mineralization defect that is commonly
seen in children with CKD [2]. Bone biopsy samples will
also be assessed by immunohistochemistry for FGF23. A
study by Pereira et al. demonstrated a correlation between
bone FGF23 expression by immunohistochemistry and
parameters of mineralization in pediatric and young adult
patients with CKD stages 2–5 [23], underscoring the importance of evaluating bone FGF23 in association with histomorphometry. Bone biopsies will be performed only at
UCLA, and there will be a separate consent form for the
procedure. Patients will remain eligible for study entry even
if they decline participation in the bone biopsy sub-study.
Participants will be withdrawn from the study if they
experience one of the following: confirmed transferrin saturation > 70%, progression to kidney failure, initiation of
phosphate binders, initiation of immunosuppression, desire
of the patient or family to discontinue participation in the
trial, loss to follow-up, or pregnancy. Medication adherence
will be critical during the conduct of the trial. Therefore, the
study will use a web-based, electronic medication adherence
monitoring system called eCAP (Information Mediary Corporation, Ottawa, ON, Canada), which is a smart medication
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bottle cap that records real-time bottle cap removal times
with an electronic timestamp. Additionally, dose reminders,
pill counters, school diary of lunch-time administration, and
self-reported adherence measures will be utilized throughout
the study.
Possible anticipated limitations of the FIT4KiD trial
relate to the use of FGF23 as the primary endpoint and
medication adherence. Although it can be hypothesized that
lowering FGF23 levels in patients with CKD may improve
clinical outcomes, to date, there have been no trials directly
targeting FGF23 to improve clinical outcomes in patients
with CKD [62]. Therefore, it is still unknown whether or not
FGF23 reduction would directly translate to improvement
in hard clinical outcomes in CKD. Additionally, medication adherence may pose a challenge. In pediatric patients
with CKD, rates of medication non-adherence are high;
specifically, medication non-adherence for phosphate binders has been reported to be ~ 20–30% [63, 64]. In the recent
COMBINE trial, which investigated the effects of lanthanum carbonate (a phosphate binder) and/or nicotinamide (an
inhibitor of intestinal phosphate transport) on phosphate and
FGF23 levels in adult patients with stage 3b/4 CKD, neither serum phosphate nor FGF23 significantly changed over
time; however, study drug discontinuation was high, ranging
from 25 to 42% across active treatment groups (compared to
14% in the placebo group), possibly limiting study conclusions [65].
In summary, the FIT4KiD trial will determine the impact
of ferric citrate on FGF23 in pediatric participants with CKD
stages 3–4. Given the associations of FGF23 with adverse
clinical outcomes, interventions that safely lower FGF23
may improve long-term patient outcomes. Importantly,
should ferric citrate safely and effectively reduce FGF23
concentrations, then the study findings may have important
implications for the optimal management of mineral bone
disorder in children with CKD.
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